Published Date: 23-Sep-2022
Industry Insights | Market Trends | Highest number of Tables | 24/7 Analyst Support
According to a new report, published by KBV research, The Global Protein Therapeutics Market size is expected to reach $490.2 billion by 2028, rising at a market growth of 6.9% CAGR during the forecast period.
The Monoclonal Antibodies market is leading the Global Protein Therapeutics Market by Product in 2021; thereby, achieving a market value of $177.1 billion by 2028. Due to the wide range of availability, significance, and usefulness of these products in the treatment of many chronic conditions, the growth of the segment is spurred at a very rapid pace. In addition, monoclonal antibodies are one of the most frequently utilized protein therapeutic products.
The Immunologic Disorders market is estimated to witness a CAGR of 6.6% during (2022 - 2028). The bolstered growth of the segment is primarily attributed to the presence of a number of immunological disorders within the healthcare sector. When a person's immune system unintentionally targets their own body, they develop an autoimmune condition.
The North America market segment shows high market share in the Global Protein Therapeutics Market by Region in 2021; thereby, achieving a market value of $180.8 billion by 2028. The Europe market is expected to witness a CAGR of 6.5% during (2022 - 2028). Additionally, The Asia Pacific market is expected to witness a CAGR of 7.7% during (2022 - 2028).
The market research report has exhaustive quantitative insights providing a clear picture of the market potential in various segments across the globe with country wise analysis in each discussed region. The key impacting factors of the market have been discussed in the report with the elaborated company profiles of Abbott Laboratories, Baxter International, Inc., Amgen, Inc., F. Hoffmann-La Roche Ltd., Eli Lilly and Company, Merck & Co., Inc., Johnson & Johnson (Janssen Global Services, LLC), Pfizer, Inc., Novo Nordisk A/S and Sanofi S.A.
Unique Offerings from KBV Research